Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino Men

Prostate Cancer Clinical Trial

— PSA  

Official title:

Informed Decision-Making Regarding PSA Screening

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00761124
• Other study ID #: 10-001693
• Secondary ID: R01CA102486
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 2003
• Est. completion date: February 2026

Study information

• Verified date: March 2024
• Source: Jonsson Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this intervention trial is aiming to increase inform decision- making in Latino men regarding prostate cancer screening.

The investigators propose to find out how much Latino men know about the benefits and risks of prostate cancer screening and what factors influence how they decide whether or not to have screening. The investigators are also interested in learning how providing education information, both verbally and in print, about the risks and benefits of prostate cancer screening affects men's interest and knowledge.

The intervention is an interactive multi-media presentation made up of a small group of 8-10 Latino men gathered to discuss about prostate cancer, screening methods, treatment, and the controversy within the medical community regarding PSA screening. A facilitator guides the 1-hour discussion and encourages participant interaction. The effect of this intervention was tested on 1000 Latino men within Los Angeles county.

Participants were recruited from 38 community venues (churches, community center, etc.). All participants were interviewed before being randomized to receive written (control group) or oral (intervention) prostate cancer education material. All of the participants will be followed up at 6-months via a telephone interview.

The investigators hypothesize that the intervention group will have an increase knowledge of prostate cancer, will have increase communication with family, friends, and medical provider, and will have an increase rate of PSA screening compared to the control group.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1006
• Est. completion date: February 2026
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

• Latino men

• 50 to 70 years old

• Not ever having prostate biopsy

• Not ever having prostate cancer

• Not having had a PSA test within the past 12 months

• Not having BPH (prostate inflammation)

• Not currently experiencing prostate problems such as pain or burning sensation during urination, blood in urine, and/or desire to urinate frequently

Exclusion Criteria:

• Not Latino

• Younger than 50 or older than 70 years old

• Currently experiencing prostate problems such as pain or burning sensations while urinating, blood in urine, and/or desire to urinate frequently

• Living outside of Los Angeles county

• Having had a prostate biopsy

• Having had prostate cancer previously

• Having had a prostatectomy

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Behavioral:
• Intervention Session
A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
• Printed Material
General prostate cancer pamphlet

Locations

Country	Name	City	State
United States	UCLA, Division of Cancer Prevention and Control Research	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
Jonsson Comprehensive Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Inform Decision-Making		6 months post-baseline interview
Secondary	Prostate cancer knowledge, Receipt of PSA, and Communication with family, friends, and medical providers		6 months post-baseline interview